Ascletis Pharma cuts losses 33%, boosts R&D spending

Ascletis Pharma reported a net loss of RMB88 million for the first half of 2025, down 32.5% from RMB130 million in the prior period. Total income doubled to RMB104 million.

R&D expenses rose 10.9% to RMB147 million, with increased investment in metabolic disease pipeline. The company held RMB1.58 billion in cash.